 high-dos etoposid marrow transplant etoposid underw convent phase dose-limit toxic studi mild myelosuppress toxic infrequ degre myelosuppress standard dose approach advantag steep dose-respons relationship chemotherapeut agent etoposid vitro clinic studi etoposid ideal agent dose-escal studi wide rang clinic antitumor activ standard dose steep dose-respons curv bone marrow suppress nonmyeloid side effect high-dos etoposid studi intens hematolog support care trial autolog marrow transplant etoposid singl agent high-dos trial mucos degre hepat dysfunct dose-limit maximum toler dose mtd set multi-ag phase etoposid cyclophosphamid total bodi irradi carmustin carboplatin dose-limit mucos toxic liver lung problem high-dos etoposid toxic mtd schedul administr etoposid continu intraven infus dose mg/kg cyclophosphamid similar toxic marrow support antitumor result lymphoma stage treatment solid tumor treatment patient sensit relaps outcom lymphoma patient respons rate overal long-term year disease-fre surviv germ cell tumor respons pattern sensit relaps improv patient patient year breast cancer small cell lung cancer sclc high-dos etoposide-contain regimen standard therapi result set good breast cancer disease-fre surviv year sclc year